FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5 |
| obligations may continue. See |
| Instruction 1(b). |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Powell Lynne | | | | | | 2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC BCRX] | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (spe | | | |
|--|---|--|---|--|---|--|-----|--|--------|---------------|---|---|---|---|--|---|--|
| (Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200 | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 12/29/2015 | | | | | | | | Senior VP - CCO | | | | |
| | | 27703 (Zip) | 4 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | 6. In Line | lividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | |
| Date | | | | . Transacti Date Month/Day | Execution Date, | | | 3. Transaction Disposed Of (D) (Instr. 3, 5) | | | | 5. Amoun Securities Beneficia Owned Fo | lly (ollowing (| 6. Owners Form: Dire (D) or Indir (I) (Instr. 4) | ect E | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | Code V | | | | A | Amount | (A) or (D) | Price | Transacti (Instr. 3 a | on(s) | | " | 11150.4) | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date if any (Month/Day/Ye | Code | action (Instr. | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficially Owned Following Reported | Owi Fori y Dire or li (I) (I | ership n: ct (D) direct nstr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Or Nu Date Expiration of | | Number | | Transaction (Instr. 4) | ii(s) | | | | |
| Emp. Stock Option (Right to Buy) | \$10.82 | 12/29/2015 | | A | | 62,573 ⁽¹⁾ | | 12/29/2016 | 5 12/ | 2/29/2025 | Common Stock | 62,573 | \$0 | 62,573 | | D | |

Explanation of Responses:

1. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

/s/ Alane P. Barnes, by power of 12/31/2015 attorney

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.